HAMP and sickle cell disease: However, due to the undesirable pharmacokinetics of unmodified hepcidin, pharmacologically suitable mimics of this peptide hormone are being investigated for application in pathologies hallmarked by iron overload, such as hereditary haemochromatosis, β-thalassaemia, and sickle cell disease [7,8].